Plain-English difference
TB-500 is an investigational peptide; prolotherapy is an in-person procedure
TB-500 is commonly sold online as a synthetic fragment or derivative related to thymosin beta-4 and promoted for tendon, ligament, muscle, joint, wound, and sports recovery. Those marketing categories do not establish a human treatment effect. Dextrose prolotherapy is different: a clinician places an irritant solution, often hypertonic dextrose, into or around a selected painful structure. Techniques, targets, solution concentrations, cointerventions, and practitioner training vary. The proposed biologic response does not make the procedure a universal regenerative treatment. These options therefore raise different evidence, quality, procedural, regulatory, rehabilitation, and follow-up questions.
- TB-500 is not an FDA-approved treatment for tendon or ligament healing, muscle repair, osteoarthritis, back pain, wound healing, pain relief, surgery recovery, or return to play.
- The use of dextrose or a clinician-performed injection does not establish that prolotherapy is FDA-approved, proven, or appropriate for every orthopedic problem.
- This guide does not provide TB-500 doses or cycles, prolotherapy concentrations or injection techniques, combination protocols, or return-to-activity timelines.
Evidence boundaries
Thymosin beta-4 biology cannot substitute for TB-500 trials, and prolotherapy findings do not transfer across diagnoses
A 2026 orthopaedic and sports-medicine primer describes thymosin beta-4 and TB-500 in the context of angiogenesis and tissue-repair biology but emphasizes that human orthopedic evidence and basic questions about safety, efficacy, indications, dosing, frequency, and duration remain unresolved. Older wound-healing research involving full-length thymosin beta-4 is not a controlled trial of seller-labeled TB-500 for tendon, joint, or sports outcomes. Prolotherapy has a separate human literature. The Department of Veterans Affairs reviewed 90 studies and found substantial variation in dextrose concentration, technique, cointerventions, comparators, and study quality. It found little to no benefit over saline for some knee-osteoarthritis outcomes, low-certainty possible benefit over saline for plantar fasciitis and lateral elbow tendinopathy, and very uncertain evidence for many other conditions and adverse effects.
- For TB-500, ask for controlled human evidence in the exact condition and route—not animal studies, full-length thymosin beta-4 results, testimonials, or seller summaries.
- For prolotherapy, ask which diagnosis, solution, target, comparator, outcome, practitioner, and rehabilitation plan the evidence actually addresses.
- Words such as angiogenesis, collagen, growth factors, inflammation, repair, or regeneration describe proposed mechanisms; they do not prove faster healing, structural recovery, surgery avoidance, or return to sport.
Diagnosis and procedure safety
Examination, urgent triage, and rehabilitation may matter more than either marketed recovery option
Musculoskeletal pain can reflect overload, tendon or ligament injury, fracture, arthritis, nerve irritation, infection, inflammatory disease, medication effects, or a post-surgical complication. Severe trauma, deformity, a sudden pop with loss of function, inability to bear weight, progressive weakness or numbness, fever, a hot swollen joint, spreading redness, drainage, calf swelling, chest pain, shortness of breath, or a nonhealing wound should not be routed into an online recovery stack. If prolotherapy is considered after diagnosis, the discussion should cover the exact solution and target, clinician qualifications, sterile technique, image guidance when appropriate, expected post-procedure symptoms, bleeding or infection risk, rehabilitation, and who handles complications.
- Review blood thinners, bleeding disorders, diabetes, immune suppression, active infection, cancer treatment, pregnancy, upcoming surgery, allergies, prior injection reactions, medicines, and supplements before a procedure or peptide discussion.
- The VA review found harms evidence very uncertain because adverse events were not consistently or adequately assessed; absence of strong harms data is not proof of safety.
- Neither TB-500 nor prolotherapy should delay physical therapy, sports medicine, orthopedics, primary care, urgent care, wound care, or emergency evaluation when symptoms warrant it.
July FDA and compounding context
The scheduled July 2026 PCAC discussion is not TB-500 approval or dosing guidance
FDA scheduled a Pharmacy Compounding Advisory Committee meeting for July 23–24, 2026 to discuss nominated peptide bulk substances, including TB-500 free base and acetate, in a section 503A compounding-policy context. The meeting has not occurred as of this page’s July 15 review date. An agenda item is not FDA approval, proof of effectiveness, a finished-drug label, a treatment recommendation, guaranteed compounding access, insurance coverage, or permission to buy a research-use vial without a prescription. Prolotherapy has a separate product-and-procedure context, so patients should ask what solution is used, what regulatory status applies to the exact product and intended use, and whether marketing is converting the ability to perform a procedure into an unsupported approval claim.
- PCAC recommendations are advisory; FDA makes final determinations after considering committee input and its reviews.
- Compounded medicines, when lawful and clinically appropriate, are individualized prescriptions and are not FDA-approved finished drug products.
- Reject “FDA released TB-500,” “approved in July,” “healing peptide now legal,” “research grade for human use,” or packages that sell a peptide and procedure before reviewing diagnosis and medical history.
Sports rules and total cost
Compare anti-doping risk, procedural quality, rehabilitation, and the complete care pathway
TB-500 presents an important sports-testing concern. Tested athletes should verify the current WADA, USADA, league, school, military, employer, and event rules before using any peptide or performance-marketed recovery product. Prolotherapy raises different practical questions: who diagnosed the condition, who performs the procedure, how response is measured, what aftercare and rehabilitation are included, and what happens if symptoms worsen or do not improve. Total cost should include evaluation, imaging when appropriate, physical therapy, procedure or prescription expense, supplies, travel, missed work or training, follow-up, and the risk of delayed diagnosis—not only a vial price or per-injection offer.
- A clinician-delivered procedure does not make a separate peptide acceptable under anti-doping rules, and a therapeutic-use process should never be assumed.
- Ask for measurable goals, reassessment timing, stop criteria, referral options, complication coverage, cancellation terms, and a realistic alternative if the plan does not help.
- No-prescription peptide checkout, vague certificates of analysis, copied cycles, hidden clinician or pharmacy identity, large prepaid procedure packages, and guaranteed return-to-play claims are red flags.